Drugs / JNJ-0440
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03915886 | Apr → Jul 2019 | — | Janssen Pharmaceutical K.K. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-0440 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03915886 ↗ |
| Known as | JNJ-64530440 | “The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of JNJ-64530440 (JNJ-0440) in healthy Japanese adult male participants after single...” NCT03915886 ↗ |
| Route | Oral | “JNJ-0440 tablets will be administered orally.” NCT03915886 ↗ |